CBT Pharmaceuticals (a US and China-based biopharmaceutical company) announced the launch of its APOLLO Oncology Clinical Trials Programme this week. The APOLLO series of trials will investigate whether the c-Met inhibitor, bozitinib (CBT-101) can work in combination with immunotherapies to improve response rates and patient outcomes.
The first study in the APOLLO programme has been initiated in Australia and New Zealand: a phase 1/2 open label, multi-centre dose escalation and expansion study in which bozitinib will be administered in combination with anti PD-1 cancer immunotherapies to people with RCC or liver cancer. Biomarkers will be used to to identify which patients are likely to benefit from the combination.
